预约演示
更新于：2025-08-16
Risankizumab-RZAA
利生奇珠单抗
更新于：2025-08-16
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国) |
登录后查看时间轴
结构/序列
Sequence Code 181110L
来源: *****
Sequence Code 181112H
来源: *****
关联
80
项与 利生奇珠单抗 相关的临床试验NCT07071519
A Phase 3, Multi-Center Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Risankizumab With Open-Label Induction, Randomized Double-Blind Maintenance, and Open-Label Long-Term Extension Periods in Pediatric Subjects (2 to < 18 Years of Age) With Moderately to Severely Active Ulcerative Colitis
NCT06880744
Phase 3b, Multicenter, Randomized, Open-Label Study of Risankizumab Compared to Vedolizumab for the Treatment of Adult Subjects With Moderate to Severe Ulcerative Colitis Who Are Naïve to Targeted Therapies
NCT07007091
A Phase 1 Pharmacokinetic Study in Healthy Subjects to Evaluate the Bioavailability of Risankizumab Subcutaneous Administration With On-Body Injector Relative to Prefilled Syringe
100 项与 利生奇珠单抗 相关的临床结果
登录后查看更多信息
100 项与 利生奇珠单抗 相关的转化医学
登录后查看更多信息
100 项与 利生奇珠单抗 相关的专利（医药）
登录后查看更多信息
658
项与 利生奇珠单抗 相关的文献（医药）2025-12-31JOURNAL OF DERMATOLOGICAL TREATMENT
Switching biologic agent in patients with psoriasis: a systematic review and meta-analysis
Review
作者: Sun, YuanQiang ; Zhao, XiTong ; Li, WenChao ; Liu, Hong ; Zhang, LiHong
BACKGROUND:
Multiple biologics are available for psoriasis treatment, but switching treatments is often necessary at some point. The choice between intraclass or interclass biologic switching has not been extensively investigated.
METHODS:
Two independent authors searched the databases PubMed and EMBASE for studies reporting on biologic switching in psoriasis patients. Our study was performed in line with the Preferred Reporting Items for Systematic Reviews and Meta Analyses (PRISMA) guidelines.
RESULTS:
A total of 19 publications, comprising 679 patients, were included. The intraclass switching group consisted of 519 patients, while the interclass switching group included 139 patients. For intraclass switching, there are respectively 160, 326 and 33 patients switched of TNF-α, IL-17, IL-23. For interclass switching, 11 patients switched from TNF-α to IL-17, 6 from IL-17 to IL-23, 41 from IL-17 to IL-12/23, 29 from IL-17 to TNF-α, 15 from IL-12/23 to IL-17, 8 from IL-12/23 to IL-23. After 12 weeks, the proportion of patients achieving Psoriasis Area and Severity Index (PASI)75 was significantly higher in the intraclass switching group compared to the interclass switching group. However, after 16-52 weeks, the PASI75 proportions were comparable between the groups.
CONCLUSION:
Intraclass switching shows better short-term efficacy than interclass switching. However, in the long term, both switching strategies are effective and safe. This study also shows that adalimumab, ixekizumab, and risankizumab are the preferred agents for intraclass switching, whereas guselkumab serves as the primary agent for interclass transitions.
2025-12-31JOURNAL OF DERMATOLOGICAL TREATMENT
Interleukin-23p19 inhibitors for the treatment of moderate-to-severe psoriasis: an expert opinion of real-world evidence studies in Europe
Review
作者: Thaçi, D. ; Ständer, S.
Background: Psoriasis is a chronic inflammatory disease affecting about 2% of the global population, with moderate-to-severe forms requiring systemic treatment for successful disease management. By targeting the interleukin (IL)-23p19 subunit of IL-23, the master cytokine of psoriasis pathogenesis, guselkumab, tildrakizumab, and risankizumab offer improved risk-benefit profiles.Objective: While randomized clinical trials (RCTs) provide controlled data, real-world evidence (RWE) offers insights into the performance of these therapies in diverse patient populations, including those with comorbidities or difficult-to-treat areas affected. With RWE on these inhibitors constantly emerging, a comprehensive overview and expert interpretation are essential for providing key insights into psoriasis management in clinical practice.Methods: This review, therefore, examined RWE on the effectiveness and safety of IL-23p19 inhibitors compared to their pivotal RCTs.Results: Despite some gaps between RCT and RWE outcomes, particularly in underrepresented subpopulations, IL-23p19 inhibitors show strong effectiveness and favorable safety across both settings in the short- and especially in the long term, accompanied by an improvement in health-related quality of life and reduction of the main symptoms.Conclusion: Altogether, these factors make these medicines ideal treatment options. Future research should focus on improving patient-reported outcomes, specifically addressing psychological and quality-of-life aspects, to further optimize psoriasis management.
2025-08-12INFLAMMOPHARMACOLOGY
A systematic review of the role of interleukin inhibitors in lichen planus: therapeutic and paradoxical effects.
Review
作者: Fathabadi, Fatemeh ; Soleimani, Sanaz ; Heidari, Amirhossein ; Heidari, Nazila ; Rasouli, Asma ; Ghanavati, Kimia
BACKGROUND:
Lichen planus (LP) is a group of chronic inflammatory disorders of the skin, mucous membranes, scalp, and nails that mainly affect the middle-aged population. Inflammatory modifiers, including interferon-α (IFN-α), IFN-γ, tumor necrosis factor-alpha (TNF-α), as well as various interleukins (ILs), such as IL-4, IL-5, IL-6, IL-8, IL-9, IL-10, IL-12, IL-17, IL-18, IL-21, IL-22, and IL-23 has also been suggested to contribute in the LP pathogenesis. We aim to systematically evaluate the effect of IL inhibitors on treating and triggering LP disease.
METHODS:
A systematic search was conducted up to January 30th, 2025, in PubMed/Medline, Web of Science, and Ovid-Embase, and clinical studies with available English full-text were included.
RESULTS:
The search recorded 196 relevant studies, with 42 articles eligible for this study. IL-inhibitors, including dupilumab, secukinumab, anakinra, tildrakizumab, guselkumab, ustekinumab, ixekizumab, risankizumab, and brodalumab were associated with clinical improvement in various types of LP. In contrast, in some cases with a coexistent autoimmune disease, such as psoriasis and atopic dermatitis, secukinumab, dupilumab, risankizumab, ustekinumab, and ixekizumab administration resulted in LP development.
CONCLUSION:
IL inhibitors demonstrate both treatment and paradoxical effects on LP. Further research is needed to elucidate the impact of these agents on the pathophysiology of LP.
100 项与 利生奇珠单抗 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 活动性中度克罗恩病 | 中国 | 2025-03-04 | |
| 活动性重度克罗恩病 | 中国 | 2025-03-04 | |
| 溃疡性结肠炎 | 日本 | 2022-09-26 | |
| 克罗恩病 | 澳大利亚 | 2019-07-16 | |
| 活动性中度溃疡性结肠炎 | 澳大利亚 | 2019-07-16 | |
| 活动性重度溃疡性结肠炎 | 澳大利亚 | 2019-07-16 | |
| 斑块状银屑病 | 加拿大 | 2019-04-17 | |
| 银屑病关节炎 | 日本 | 2019-03-26 | |
| 红皮病性银屑病 | 日本 | 2019-03-26 | |
| 寻常性银屑病 | 日本 | 2019-03-26 | |
| 脓疱型银屑病 | 日本 | 2019-03-26 | |
| 手掌和足底脓疱病 | 日本 | 2019-03-26 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 幼年特发性关节炎 | 临床3期 | 美国 | 2024-07-08 | |
| 幼年特发性关节炎 | 临床3期 | 澳大利亚 | 2024-07-08 | |
| 幼年特发性关节炎 | 临床3期 | 加拿大 | 2024-07-08 | |
| 幼年特发性关节炎 | 临床3期 | 法国 | 2024-07-08 | |
| 幼年特发性关节炎 | 临床3期 | 德国 | 2024-07-08 | |
| 幼年特发性关节炎 | 临床3期 | 意大利 | 2024-07-08 | |
| 幼年特发性关节炎 | 临床3期 | 波兰 | 2024-07-08 | |
| 幼年特发性关节炎 | 临床3期 | 西班牙 | 2024-07-08 | |
| 幼年特发性关节炎 | 临床3期 | 英国 | 2024-07-08 | |
| 掌跖角化病 | 临床3期 | 美国 | 2021-02-26 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 139 | (Part 1: Risankizumab) | 網範製網構淵衊夢鏇夢 = 網築夢鬱範選遞窪醖網 鹹鬱遞蓋觸鏇簾繭醖餘 (繭醖顧齋齋遞顧願範積, 醖膚選獵獵膚壓夢夢淵 ~ 糧遞觸窪糧廠膚醖壓顧) 更多 | - | 2025-05-20 | ||
Ustekinumab (Part 2 Period A: Ustekinumab) | 網範製網構淵衊夢鏇夢 = 衊構鑰糧製鏇衊獵鏇壓 鹹鬱遞蓋觸鏇簾繭醖餘 (繭醖顧齋齋遞顧願範積, 蓋願蓋範餘觸衊膚醖廠 ~ 簾鬱餘製壓觸鬱獵製積) 更多 | ||||||
临床3期 | 748 | Risankizumab 600 mg | 願選蓋鏇齋壓繭壓壓簾(範製壓繭觸選積範憲鬱) = 願壓繭範鏇醖壓衊觸淵 願鬱選繭餘顧憲壓願製 (膚窪製築選顧遞艱選獵 ) 更多 | 积极 | 2025-04-04 | ||
Risankizumab 180 mg | 願選蓋鏇齋壓繭壓壓簾(範製壓繭觸選積範憲鬱) = 築夢蓋鑰蓋選觸繭鹹蓋 願鬱選繭餘顧憲壓願製 (膚窪製築選顧遞艱選獵 ) 更多 | ||||||
临床3期 | 克罗恩病引起的肛周瘘 anti-interleukin-23 p19 monoclonal antibody | - | Risankizumab 1200 mg IV | 鬱鹹鏇鬱齋廠觸網願壓(廠餘築膚淵鬱選鏇鏇淵) = 願襯鑰衊鹽遞糧醖醖鏇 糧醖遞積鹹齋壓艱遞壓 (築糧淵願繭窪觸淵襯獵 ) 更多 | 积极 | 2025-02-01 | |
Risankizumab 180 mg SC | 鬱鹹鏇鬱齋廠觸網願壓(廠餘築膚淵鬱選鏇鏇淵) = 製廠製鑰憲餘鑰壓顧鹹 糧醖遞積鹹齋壓艱遞壓 (築糧淵願繭窪觸淵襯獵 ) 更多 | ||||||
临床3期 | 克罗恩病 维持 | - | 鬱鹽膚獵網鏇簾蓋餘淵(鬱鑰壓構憲繭襯醖遞鬱) = 鹹築願糧醖淵築夢構鹹 觸壓醖簾顧遞顧簾鏇顧 (網壓艱築夢餘鹹糧廠壓 ) | 积极 | 2025-01-01 | ||
临床3期 | 2,170 | 衊艱鹽鹽鏇遞網簾齋醖 = 憲繭鑰願鏇構淵繭鹹醖 鬱蓋餘醖構壓觸憲網齋 (鏇窪糧淵簾簾鏇鬱壓願, 齋觸憲醖膚醖鹹壓艱餘 ~ 築醖衊願醖範築餘鏇選) 更多 | - | 2024-12-11 | |||
| - | - | 98 | 構鑰鬱選齋遞鏇觸窪醖(壓糧築繭壓觸鑰選積鹽) = 醖廠憲願遞餘壓構網膚 襯齋鏇遞壓鑰窪醖淵窪 (鬱齋鹽衊積襯願鏇遞遞 ) 更多 | 优效 | 2024-12-07 | ||
甲氨蝶呤 | 構鑰鬱選齋遞鏇觸窪醖(壓糧築繭壓觸鑰選積鹽) = 遞艱顧範獵鏇憲鹽範積 襯齋鏇遞壓鑰窪醖淵窪 (鬱齋鹽衊積襯願鏇遞遞 ) 更多 | ||||||
临床3期 | - | 鹽築鬱夢觸觸膚鏇繭艱(鑰製憲餘襯簾憲顧鑰廠) = 顧願簾淵網築範衊繭製 壓餘觸簾衊願簾壓鹹齋 (獵觸網網觸簾糧衊窪鑰, 48.2 ~ 79.6) 更多 | 积极 | 2024-10-13 | |||
Ustekinumab | 鹽築鬱夢觸觸膚鏇繭艱(鑰製憲餘襯簾憲顧鑰廠) = 窪壓鏇願餘醖蓋壓壓網 壓餘觸簾衊願簾壓鹹齋 (獵觸網網觸簾糧衊窪鑰, 36.2 ~ 66.1) 更多 | ||||||
临床3期 | 难治性乳糜泻 C-reactive protein (CRP) | faecal calprotectine (FC) | 417 | 糧鬱構壓簾築夢鑰襯鏇(糧積網糧顧蓋廠鏇窪網) = 23 patients (5.5%) presented adverse events including 6 infections 餘網願遞鹹願積鹹顧範 (鏇襯壓壓鹹鹽選網衊鏇 ) 更多 | 积极 | 2024-10-13 | ||
N/A | - | Risankizumab 1200 mg IV | 鑰簾艱製築範窪繭鹹艱(觸襯鏇蓋餘簾遞築遞選) = 鏇窪顧積鏇糧願鬱顧窪 衊襯構蓋淵獵糧艱鏇膚 (鑰蓋製蓋觸壓築構醖獵 ) | - | 2024-10-13 | ||
Placebo IV | 鑰簾艱製築範窪繭鹹艱(觸襯鏇蓋餘簾遞築遞選) = 艱餘遞鑰範網醖網糧膚 衊襯構蓋淵獵糧艱鏇膚 (鑰蓋製蓋觸壓築構醖獵 ) | ||||||
临床3期 | 克罗恩病 high-sensitivity C-reactive protein | fecal calprotectin | - | 繭鑰繭遞膚蓋網壓窪襯(願觸齋範範齋遞構顧獵) = 鏇醖淵夢鬱範構糧簾製 糧糧積製醖積鑰夢艱鏇 (糧顧製醖壓憲餘鬱觸壓, 22.0 ~ 35.6) 更多 | 积极 | 2024-10-13 | ||
Ustekinumab | 繭鑰繭遞膚蓋網壓窪襯(願觸齋範範齋遞構顧獵) = 鑰鬱顧糧繭齋選顧築範 糧糧積製醖積鑰夢艱鏇 (糧顧製醖壓憲餘鬱觸壓, 8.8 ~ 18.9) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
生物类似药
生物类似药在不同国家/地区的竞争态势。请注意临床1/2期并入临床2期，临床2/3期并入临床3期
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用